- Home
- JBGS vs EWTX Comparison
JBGS vs EWTX Comparison
Compare JBGS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- EWTX
- Stock Information
- Founded
- JBGS 2016
- EWTX 2017
- Country
- JBGS United States
- EWTX United States
- Employees
- JBGS 645
- EWTX N/A
- Industry
- JBGS Real Estate Investment Trusts
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- JBGS Real Estate
- EWTX Health Care
- Exchange
- JBGS Nasdaq
- EWTX Nasdaq
- Market Cap
- JBGS 1.3B
- EWTX 1.2B
- IPO Year
- JBGS 2017
- EWTX 2021
- Fundamental
- Price
- JBGS $17.84
- EWTX $14.30
- Analyst Decision
- JBGS Sell
- EWTX Buy
- Analyst Count
- JBGS 2
- EWTX 8
- Target Price
- JBGS $16.00
- EWTX $39.63
- AVG Volume (30 Days)
- JBGS 1.5M
- EWTX 932.9K
- Earning Date
- JBGS 07-29-2025
- EWTX 08-07-2025
- Dividend Yield
- JBGS 3.96%
- EWTX N/A
- EPS Growth
- JBGS N/A
- EWTX N/A
- EPS
- JBGS N/A
- EWTX N/A
- Revenue
- JBGS $520,825,000.00
- EWTX N/A
- Revenue This Year
- JBGS N/A
- EWTX N/A
- Revenue Next Year
- JBGS $2.71
- EWTX N/A
- P/E Ratio
- JBGS N/A
- EWTX N/A
- Revenue Growth
- JBGS N/A
- EWTX N/A
- 52 Week Low
- JBGS $13.28
- EWTX $10.60
- 52 Week High
- JBGS $18.86
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- JBGS 58.04
- EWTX 41.90
- Support Level
- JBGS $17.58
- EWTX $14.87
- Resistance Level
- JBGS $18.50
- EWTX $15.68
- Average True Range (ATR)
- JBGS 0.61
- EWTX 0.67
- MACD
- JBGS -0.04
- EWTX -0.02
- Stochastic Oscillator
- JBGS 55.59
- EWTX 15.25
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.